Evidence map›Paper›PMID 25458560›Full record

ArticleClinical lung cancer2015

Lung cancer hormesis in high impact states where nuclear testing occurred.

Steven Lehrer, Kenneth E Rosenzweig

Abstract read
In one paragraph

Article in Clinical lung cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. The Lowest Radiation Dose Having Molecular Changes in the Living Body.Dose-response : a publication of International Hormesis Society
    Article
  17. Reduced Lung Cancer Mortality With Lower Atmospheric Pressure.Dose-response : a publication of International Hormesis Society
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Steven LehrerDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, NY. Electronic address: steven.lehrer@mssm.edu.
Kenneth E RosenzweigDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, NY.
Icahn School of Medicine at Mount Sinai · US

Funding

POLYMORPHIC ESTROGEN RECEPTOR M-RNA IN BREAST CANCERR01CA049506 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF CUNY · PI LEHRER, STEVEN P · 1989 to 1991
–
NCI NIH HHS R01 CA049506
6 · The paper itself

Abstract

backgroundHormesis is a favorable biological response to low toxin exposure. In the case of radiation, large doses are carcinogenic, but low doses might be protective. In the current study, we analyzed lung cancer incidence in high-impact radiation states where nuclear testing occurred and compared it with lung cancer incidence in the remaining normal-impact radiation states and the District of Columbia. MATERIALS AND

methodsLung cancer incidence data were from the American Cancer Society. Tobacco use 2012 data were from the Centers for Disease Control and Prevention. The distribution of states grouped according to lung cancer incidence interval was from the Centers for Disease Control and Prevention. Total background radiation measurements (terrestrial + cosmic + radon) were from Assessment of Variations in Radiation Exposure in the United States (2005). Data on high- and normal-impact states were from the National Radiation Exposure Screening & Education Program (RESEP). Congress passed the Radiation Exposure Compensation Act Amendments of 2000, creating RESEP, to help thousands of people diagnosed with cancer and other diseases caused by exposure to nuclear fallout or radioactive materials such as uranium. These people live in 12 high-impact states where nuclear testing had occurred. High-impact states were not designated according to measurements of background radiation.

resultsLung cancer incidence is significantly lower in high-impact states in men (t = 5.4 for unequal variance; P < .001) and women (t = 3.0; P < .001). The clustering of the 12 high-impact states in the 2 lowest lung cancer incidence intervals (26.8-56.9 and 57.0-63.2) is statistically significant (P < .001, Fisher exact test, 2-tailed). Because cigarette smoking is ordinarily the most powerful risk factor for lung cancer, multivariate linear regression analysis of the effect of U.S. state group (normal-impact, high-impact, or extra high-impact for Nevada, Utah, and Arizona) on lung cancer incidence in men and women was performed. (In Nevada, Utah, and Arizona, men and women would have been downwind.) The U.S. state group impact was significant (P < .001 for men; P = .015 for women). The effect of percentage of smokers in the population was significant (P < .001 for men; P < .001 for women). The effect of total background radiation was significant (P = .029 for men; P < .029 for women); like the state group impact, more background radiation exposure was associated with less lung cancer.

conclusionHormesis is still mired in controversy. Yet, it is of vital medical importance because of the continuing debate over whether the low-level radiation doses from diagnostic x-ray procedures, such as computed tomography scans, are harmful. Our analysis adds to the body of evidence suggesting that the linear no threshold model of radiation carcinogenicity in lung cancer might not be correct. Low-level radiation exposure might protect against lung cancer rather than cause it.

Indexed as

Radioactive FalloutAmerican Cancer SocietyEnvironmental ExposureFemaleHormesisHumansIncidenceLinear ModelsLung NeoplasmsMaleMultivariate AnalysisNuclear WeaponsRisk FactorsSex DistributionSmokingUnited StatesRadioactive FalloutBackgroundLinear no threshold modelRadiation

Identifiers

PMID25458560
PMCPMC6587186
OpenAlexW2110302270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.